Stricker B H, Ottervanger J P
Bureau Bijwerkingen Geneesmiddelen, Rijswijk.
Ned Tijdschr Geneeskd. 1992 Sep 5;136(36):1774-6.
Since the registration of sumatriptan (Imigran) in May 1991, the Netherlands Centre for Monitoring of Adverse Reactions to Drugs received 13 reports of substernal chest tightness or pain attributed to its use. These concerned 11 women and two men with an average age of 41 years, who developed angina-like symptoms mostly within one hour after oral or subcutaneous administration. Electrocardiography (in three patients) and echocardiography (in one patient), performed after resolution of the symptoms, were normal. With the exception of one patient, none had experienced such symptoms before. Although sumatriptan is an effective anti-migrainous drug, cautious use is strongly advised. Sumatriptan is contraindicated in patients with coronary artery disease or variant angina pectoris.
自舒马曲坦（英明格）于1991年5月注册以来，荷兰药物不良反应监测中心收到了13例因使用该药而出现胸骨后胸闷或疼痛的报告。这些报告涉及11名女性和2名男性，平均年龄为41岁，他们大多在口服或皮下给药后一小时内出现心绞痛样症状。症状缓解后进行的心电图检查（3例患者）和超声心动图检查（1例患者）均正常。除1例患者外，之前均未出现过此类症状。尽管舒马曲坦是一种有效的抗偏头痛药物，但强烈建议谨慎使用。冠心病或变异型心绞痛患者禁用舒马曲坦。
